Glimepiride, Metformin HCI (ER) & Voglibose Tablets

Coravog-GM2 by Corazon is a trusted triple combination anti-diabetic therapy formulated for effective management of Type 2 Diabetes Mellitus (T2DM). The synergistic action of Glimepiride, Metformin Hydrochloride (ER), and Voglibose provides holistic glycemic control by targeting multiple pathways, making it a reliable choice for patients who require combination therapy.

Composition (Each film-coated tablet contains):

• Metformin Hydrochloride IP (ER) – 500 mg
• Glimepiride IP – 2 mg
• Voglibose IP – 0.2 mg

How Coravog-GM2 (Voglibose 0.2mg + Glimepiride 2mg + Metformin Hydrochloride 500mg) Works -
Glimepiride stimulates pancreatic β-cells to release insulin, lowering blood glucose. Metformin (ER) Enhances insulin sensitivity, reduces hepatic glucose production, and ensures sustained glucose control. Voglibose inhibits intestinal α-glucosidase enzyme, delaying carbohydrate absorption and controlling post-meal sugar spikes.​​​​​​​